Debt-to-equity of AEON Biopharma, Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
AEON Biopharma, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • AEON Biopharma, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -149%, a 43% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

AEON Biopharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -149% -45% -43% 30 Sep 2025
Q2 2025 -137% -31% -29% 30 Jun 2025
Q1 2025 -127% -21% -20% 31 Mar 2025
Q4 2024 -106% +3% +2.8% 31 Dec 2024
Q3 2024 -105% -34% -47% 30 Sep 2024
Q2 2024 -107% -51% -93% 30 Jun 2024
Q1 2024 -106% -51% -91% 31 Mar 2024
Q4 2023 -109% -52% -93% 31 Dec 2023
Q3 2023 -71% +33% +32% 30 Sep 2023
Q2 2023 -55% +57% +51% 30 Jun 2023
Q1 2023 -55% +56% +51% 31 Mar 2023
Q4 2022 -56% +57% +50% 31 Dec 2022
Q3 2022 -104% +76% +42% 30 Sep 2022
Q2 2022 -112% 30 Jun 2022
Q1 2022 -112% 31 Mar 2022
Q4 2021 -113% 31 Dec 2021
Q3 2021 -181% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.